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Membrane transporters are found throughout the body, where they are responsible for many 
vital functions. Important representatives of membrane transporters are P-glycoprotein 
(ABCB1), Breast cancer resistance protein (ABCG2) and multidrug resistance-associated 
protein 2 (ABCC2) belonging to the ATP-biding Cassette (ABC) family. Nucleoside transporters 
belonging to Solute Carriers family (SLC) transporters represent another important group. It 
has been well evidenced that these transporters also affect drug disposition and contribute to 
tumor resistance to anticancer therapy. Over working on this dissertation thesis, we 
investigated the mentioned transporters (with special focus on nucleoside transporters) in 
complex fashion. We described the expression profile of nucleoside transporters in the 
placenta at different stages of gestation. We also examined whether the expression of 
nucleoside transporters changes depending on the degree of differentiation or can be affected 
epigenetically, and we demonstrated the importance of the cAMP / protein kinase A signaling 
pathway in their regulation. Regarding drug disposition, we found that placental equilibrative 
nucleoside transporter 1 significantly facilitates mather-to-fetus transfer of nucleoside-derive 
drugs, anti-HIV abacavir and anti-HCV ribavirin, but do not affect placental kinetics of anti-HIV 
drugs, emtricitabine and zidovudine. Similarly, ABC transporters providing fetal protection did 
not reduce maternal-fetal transfer of ribavirin. We also addressed the role of equilibrative 
nucleoside transporter 1 in the chemoresistance of pancreatic ductal adenocarcinoma to 
adjuvant gemcitabine therapy. Within our cohort of patients, we were unable to confirm the 
correlation between equilibrative nucleoside transporter 1 expression and patients’ survival. 
We achieved a similar result in the analysis of other potential prognostic markers neurogenic 
locus notch homolog protein 3 (NOTCH3) and microRNA 21 (miR-21). Our data and published 
studies have broadened knowledge on the regulation of nucleoside transporters and their 
involvement in drug pharmacokinetics, as well as they evidenced lacking involvement of ABC 
transporters in the placental kinetics of nucleoside analogs. 
